SCHEMBL7177481

SCHEMBL7177481

COC(C)Oc1ccc(PC(=O)c2c(Cl)cccc2Cl)c(OC(C)OC)c1.[LiH]

nearest known ligand 0.33

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.33
KMT2A Q03164 3/20 0.33
CXCL12 P48061 1/20 0.32
ALDH1A1 P00352 1/20 0.32
ABCG2 Q9UNQ0 2/20 0.32
CARM1 Q86X55 1/20 0.32
PRMT6 Q96LA8 1/20 0.32
ITGB1 P05556 1/20 0.31
ITGA4 P13612 1/20 0.31
MEN1 O00255 2/20 0.31
PTGS2 P35354 1/20 0.31
LMNA P02545 1/20 0.31
OGG1 O15527 1/20 0.31
ELANE P08246 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
FLT3 P36888 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7180392 0.95 MAPT (0.38) SMN1; SMN2KMT2ACXCL12ABCG2ITGB1
SCHEMBL7179731 0.94 ABL1 (0.33) SMN1; SMN2KMT2ACXCL12ITGB1ITGA4
SCHEMBL7182468 0.88 FFAR1 (0.34) KMT2ACARM1PRMT6MEN1ELANE
SCHEMBL7181155 0.88 KMT2A (0.33) KMT2AALDH1A1MEN1
SCHEMBL7184605 0.88 MAPT (0.40) SMN1; SMN2KMT2AALDH1A1ABCG2
SCHEMBL7190032 0.87 RORC (0.37) SMN1; SMN2KMT2AALDH1A1MEN1LMNA
SCHEMBL7175696 0.86 SMN1; SMN2 (0.33) SMN1; SMN2KMT2ACXCL12ALDH1A1ABCG2
SCHEMBL7182533 0.86 FFAR1 (0.36) SMN1; SMN2KMT2ACXCL12ALDH1A1ABCG2
Lithium SCHEMBL7186703 0.85 TDP1 (0.35) SMN1; SMN2KMT2AALDH1A1ITGB1ITGA4
Lithium SCHEMBL7190038 0.85 RORC (0.37) SMN1; SMN2KMT2AALDH1A1MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 SMN1; SMN2 2939/4885KMT2A 1586/4885CXCL12 4465/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 SMN1; SMN2 3105/4885KMT2A 956/4885CXCL12 4589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.